News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Scil Proteins GmbH Signs Research Collaboration with the Martin Luther-University Halle-Wittenberg for Gastrointestinal Tumors



8/16/2011 11:00:19 AM

Halle, Germany, 16 August, 2011 – Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, today announced that it has signed a collaboration agreement with the Martin Luther University Halle-Wittenberg to research innovative therapies for gastrointestinal tumors.

The project will be run by Professor Dr. Thomas Seufferlein, head of the University Hospital’s gastroenterology clinic, and will focus on the discovery and characterisation of disease-related molecular structures. Scil Proteins will then use the Company’s proprietary Affilin® platform to identify effective therapeutics and advance them into further clinical development.

Scil Proteins’ Affilin® therapeutics are so called scaffold proteins derived from the human protein Ubiquitin. Affilin® molecules are high affinity binders with excellent target specificity. The Affilin® platform has successfully delivered target specific molecules, which have subsequently shown activity in animal models, within only a few months.

Dr. Ulrike Fiedler, CEO of Scil Proteins, commented: “We are very pleased to have signed this research collaboration with the Martin Luther University Halle-Wittenberg. We look forward to working with Professor Dr. Seufferlein’s team and using our Affilin® technology to discover innovative therapies for gastrointestinal tumors. We hope that the project will allow us to develop new therapeutic options for patients suffering from gastrointestinal cancer.”

About Scil Proteins

Scil Proteins is a biopharmaceutical company discovering and developing Affilin® molecules and working with industry partners in the development and manufacture of protein therapeutics and diagnostics. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins’ discovery platform is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems. Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer and other therapeutic areas. It also offers the technology to industry for collaborative discovery and development partnerships. With a longstanding expertise in protein production and development, Scil Proteins also offers GMP contract biomanufacturing and process development to biotech and pharma companies. Scil Proteins is a well-established private company located in Halle, Germany. To learn more about Scil Proteins please visit www.scilproteins.com

Contact

Scil Proteins GmbH

Frank Ubags

CFO

t: (Germany) +49 (0) 345 27 99 63 30

e: frank.ubags@scilproteins.com

College Hill

Lauren McConville– Account Manager– Munich

t: (Germany) +49 (0) 89 52 05 92 12

e: scilproteins@collegehill.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES